It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
A new variant of Streptococcus pyogenes serotype M1 (designated ‘M1UK’) has been reported in the United Kingdom, linked with seasonal scarlet fever surges, marked increase in invasive infections, and exhibiting enhanced expression of the superantigen SpeA. The progenitor S. pyogenes ‘M1global’ and M1UK clones can be differentiated by 27 SNPs and 4 indels, yet the mechanism for speA upregulation is unknown. Here we investigate the previously unappreciated expansion of M1UK in Australia, now isolated from the majority of serious infections caused by serotype M1 S. pyogenes. M1UK sub-lineages circulating in Australia also contain a novel toxin repertoire associated with epidemic scarlet fever causing S. pyogenes in Asia. A single SNP in the 5’ transcriptional leader sequence of the transfer-messenger RNA gene ssrA drives enhanced SpeA superantigen expression as a result of ssrA terminator read-through in the M1UK lineage. This represents a previously unappreciated mechanism of toxin expression and urges enhanced international surveillance.
A variant of group A Streptococcus serotype M1 (UK) has been increasingly reported and can be differentiated from the global variant by its overexpression of the superantigen SpeA. Here, Davies et al probe the mechanism behind enhanced SpeA expression and demonstrate that a SNP in the 5’ leader sequence of ssrA is responsible for this virulence phenotype.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Keller, Nadia 2 ; Brouwer, Stephan 2
; Jespersen, Magnus G. 1
; Cork, Amanda J. 2
; Hayes, Andrew J. 1
; Pitt, Miranda E. 1
; De Oliveira, David M. P. 2
; Harbison-Price, Nichaela 2
; Bertolla, Olivia M. 2 ; Mediati, Daniel G. 3 ; Curren, Bodie F. 2
; Taiaroa, George 1 ; Lacey, Jake A. 4
; Smith, Helen V. 5
; Fang, Ning-Xia 5 ; Coin, Lachlan J. M. 1 ; Stevens, Kerrie 6 ; Tong, Steven Y. C. 7
; Sanderson-Smith, Martina 8
; Tree, Jai J. 3 ; Irwin, Adam D. 9
; Grimwood, Keith 10 ; Howden, Benjamin P. 6
; Jennison, Amy V. 5 ; Walker, Mark J. 2
1 The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
2 The University of Queensland, Australian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences and Institute for Molecular Bioscience, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
3 University of New South Wales, School of Biotechnology and Biomolecular Sciences, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)
4 The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Department of Infectious Diseases, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
5 Queensland Health Forensic and Scientific Services, Queensland Health, Public Health Microbiology, Coopers Plains, Australia (GRID:grid.415606.0) (ISNI:0000 0004 0380 0804)
6 The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Microbiological Diagnostic Unit Public Health Laboratory, The Department of Microbiology and Immunology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
7 The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Department of Infectious Diseases, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); at the Peter Doherty Institute for Infection and Immunity, Victorian Infectious Diseases Service, The Royal Melbourne Hospital, Melbourne, Australia (GRID:grid.483778.7)
8 University of Wollongong, Illawarra Health and Medical Research Institute and Molecular Horizons, School of Chemistry and Molecular Bioscience, Wollongong, Australia (GRID:grid.1007.6) (ISNI:0000 0004 0486 528X)
9 University of Queensland Centre for Clinical Research, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); Queensland Children’s Hospital, Brisbane, Australia (GRID:grid.240562.7)
10 Griffith University, School of Medicine and Dentistry and Menzies Health Institute Queensland, Gold Coast, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432); Gold Coast Health, Departments of Infectious Diseases and Paediatrics, Gold Coast, Australia (GRID:grid.507967.a)




